Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 1
1999 1
2000 3
2001 1
2002 1
2003 2
2005 4
2006 1
2008 1
2018 2
2020 1
2021 1
2022 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
Kutsch N, Pallasch C, Decker T, Hebart H, Chow KU, Graeven U, Kisro J, Kroeber A, Tausch E, Fischer K, Fink AM, Wendtner CM, Ritgen M, Stilgenbauer S, Zhang D, Li B, Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M, Eichhorst B. Kutsch N, et al. Among authors: kisro j. Hemasphere. 2022 May 25;6(6):e729. doi: 10.1097/HS9.0000000000000729. eCollection 2022 Jun. Hemasphere. 2022. PMID: 35747845 Free PMC article. No abstract available.
[Venous catheter-associated infections in patients with neutropenia].
Fätkenheuer G, Buchheidt D, Fuhr HG, Heussel G, Junghanss C, Karthaus M, Kellner O, Kern WV, Kisro J, Sezer O, Südhoff T, Szelényi H; Arbeitsgemeinschaft Infektiologie in der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO). Fätkenheuer G, et al. Among authors: kisro j. Dtsch Med Wochenschr. 2001 Jan 26;126(4):89-95. doi: 10.1055/s-2001-10666. Dtsch Med Wochenschr. 2001. PMID: 11218567 Review. German. No abstract available.
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Stilgenbauer S, Bosch F, Ilhan O, Kisro J, Mahé B, Mikuskova E, Osmanov D, Reda G, Robinson S, Tausch E, Turgut M, Wójtowicz M, Böttcher S, Perretti T, Trask P, Van Hoef M, Leblond V, Foà R. Stilgenbauer S, et al. Among authors: kisro j. Br J Haematol. 2021 Apr;193(2):325-338. doi: 10.1111/bjh.17326. Epub 2021 Feb 19. Br J Haematol. 2021. PMID: 33605445 Clinical Trial.
Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite.
Brüggemann SK, Radike K, Braasch K, Hinrichs J, Kisro J, Hagenah W, Peters SO, Wagner T. Brüggemann SK, et al. Among authors: kisro j. Cancer Chemother Pharmacol. 2006 Feb;57(3):349-56. doi: 10.1007/s00280-005-0061-0. Epub 2005 Aug 25. Cancer Chemother Pharmacol. 2006. PMID: 16133533
New insights into the clinical pharmacokinetics of trofosfamide.
Brinker A, Kisro J, Letsch C, Brüggemann SK, Wagner T. Brinker A, et al. Among authors: kisro j. Int J Clin Pharmacol Ther. 2002 Aug;40(8):376-81. doi: 10.5414/cpp40376. Int J Clin Pharmacol Ther. 2002. PMID: 12467306 Clinical Trial.
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
Leblond V, Aktan M, Ferra Coll CM, Dartigeas C, Kisro J, Montillo M, Raposo J, Merot JL, Robson S, Gresko E, Bosch F, Stilgenbauer S, Foà R. Leblond V, et al. Among authors: kisro j. Haematologica. 2018 Nov;103(11):1889-1898. doi: 10.3324/haematol.2017.186387. Epub 2018 Jul 5. Haematologica. 2018. PMID: 29976743 Free PMC article. Clinical Trial.
20 results